AllDocs -> cancers

Feline leukaemia virus Feline Advisory Bureau About FAB Membership Make a donation Boarding Catteries Books for cat lovers Cat Group Conferences ESFM FAB Publications FAB Lecturers/residents Info for breeders Info for cat owners Info for veterinary nurses PKD scheme Feline leukaemia virus - FeLV Feline leukaemia virus (FeLV) is a common and important cause of illness and death in pet cats. Cats that become persistently (permanently) infected with this virus are at risk of developing many severe illnesses such as anaemia and cancer. Between 80 and 90% of infected cats die within three and a half years of being diagnosed as having FeLV. The most common effect of infection is immunosuppression. The virus infects cells of the immune system (the white blood cells) killing or damaging them. ...

1 (REVISED VERSION) ASSESSMENT OF THE RESPONSE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS – COMPARISON BETWEEN THE FISH, MULTIPLEX AND REAL-TIME RT-PCR METHODS Pia Raanani a,b,* , Isaac Ben-Bassat a,b , Shlomit Gan a , Luba Trakhtenbrot a , Ziva Mark a , Osnat Ashur-Fabian a , Svetlana Itskovich a , Frida Brok- Simoni a,b , Gideon Rechavi a,b , Ninette Amariglio a , Arnon Nagler a,b a The Institute of Hematology, The Chaim Sheba Medical Center , Tel- Hashomer and b Sackler School of Medicine, Tel-Aviv University, Israel *Corresponding author: Pia Raanani Institute of Hematology The Chaim Sheba Medical Center ...

leukaemia UK & IRELAND FORUM ON CHRONIC MYELOID LEUKAEMIA Fri 7th/ Sat 8th MAY 2004 VENUE: Roxburghe Hotel, 38 Charlotte Square, EDINBURGH EH2 4HG Tel : 0131 240 5500 REGISTRATION FORM SURNAME: FIRST NAME(S): JOB TITLE: HOSPITAL & FULL ADDRESS: TELEPHONE NO: .? FAX NO: .? E-MAIL ADDRESS: ...

CONFIDENTIAL Version 1.0 17 th January 2003 CONFIDENTIAL 1 HTLV-I ASSOCIATED ADULT T-CELL LEUKAEMIA /LYMPHOMA (ATLL) PILOT STUDY OF COMBINATION THERAPY WITH CHOP-Zenapax (CHOP-daclizumab) Protocol Version Version 1.0, 17 th January 2003 Principal Investigator Dr Antonio Pagliuca Signature: Address Dept of Haematological Medicine, Guys, Kings, Thomas’ School of Medicine, Kings College Hospital, Denmark Hill, London, SE5 9RS. Phone (0044) 0207-346-3709 Email antonio.pagliuca@kcl.ac.uk Page 2 CONFIDENTIAL Version 1.0 17 th January 2003 CONFIDENTIAL 2 Study Personnel: Primary Investigators: Dr Antonio Pagliuca Department of Haematological Medicine ...

2 CHRONIC MYELOID LEUKAEMIA 1.0 stick PATIENT label here 2.0 Referral Details 2.1 2.2 G.P. specify_ 2.3 2.4 Clinical Presentation (specify) __ 2.4.1 2.5 Provisional diagnosis : _ 2.6 Yes No specify _ 2.7 Previous: Radiotherapy other specify 2.8 Strong family history of any malignant disease Yes No UNK If YES 2 or more 1st degree relatives: 2.9 Previous solid organ transplant Yes No Generic Data Items HAEMATOLOGY Minimum Cancer Data Set :- Chemotherapy Date of receipt of referral __ Referred to Source of referral Cons.to Cons. Self Referral Other inc Private DATE OF 1st APPOINTMENT Previous or concurrent malignant disease: Diagnosis & Treatment initiated elsewhere no need to complete. signature ...

Department of Health BROWNES DAIRY SUPPORT CENTRE FOR CANCER & LEUKAEMIA Ground Floor E Block Hospital Avenue, Nedlands, Western Australia 6009 Phone: 93467632 Email: David.J.Oliver@health.wa.gov.au t tt . ABOUT THE SUPPORT CENTRE The Support Centre is a unique new patient support service in the Metropolitan area. It is housed in a purpose built Centre in SCGH and is becoming an integral part of ongoing patient care. The Centre is a place where cancer patients can access information from a variety of resources and support groups and a place where all cancer patients and their carers in Western Australia can try various complementary therapies free of charge in a safe environment. There is no need for a referral from their doctor. Recent advances in oncology now see the delivery of supportive complementary care to patients with ...

leukaemia Anti-CD33 engineered lymphocytes for the treatment of myeloid leukaemia . Dr. Peter J. Nicholls Department of Biosciences University of Kent at Canterbury Acute Myeloid Leukaemia (AML) Characterised by proliferation of myeloid cells in the bone marrow. In the USA, annual incidence of the disease is 2.4 per 100,000 people, increasing to 12.6 per 100,000 at >65 years of age. Prior to 1970, 5 year survival rates <15% Recent refinements in diagnosis/therapy have improved outlook for AML patients. Nevertheless, survival rate for patients <65 years old is just 40%. Source: NEJM 341 (14), 1051 [1999] Clinical Presentation in AML Clinical signs (e.g. fatigue, haemorrage, infection, dyspnea) are initially diverse and non-specific, making diagnosis problematic. Leukaemic infiltration of liver, spleen, skin, lymph ...

l del file contenuto in http://homepages.uel.ac.uk/u0113220/MONOCLONAL%20ANTIBODIES.ppt . G o o g l e crea automaticamente la versione .html dei documenti durante la scansione del Web. Per inserire un segnalibro o un collegamento alla pagina, utilizzare il seguente URL: http://www.google.com/search?q=cache:M-4yzJHguBoJ:homepages.uel.ac.uk/u0113220/MONOCLONAL%2520ANTIBODIES.ppt+allintitle:+leukaemia+filetype:pdf+OR++filetype:doc+OR+filetype:ppt+OR++filetype:xls+OR+filetype:rtf&hl=it&lr=lang_en Google non è collegato agli autori di questa pagina e non è responsabile del suo contenuto. I termini specificati sono presenti solamente in collegamenti che rimandano alla seguente pagina: allintitle leukaemia MONOCLONAL ANTIBODIES SEMINAR PRESENTATION Performed by PASCHALIS KOURELIAS MSc BIOMEDICAL IMMUNOLOGY EAST LONDON UNIVERSITY STRATFORD 09 /12/2003 ...

www.ijmm.org HIV-1 INFECTION IN A PATIENT OF ACUTE LYMPHOCYTIC LEUKAEMIA MISSED BY HIV-SPOT AND HIV-SCAN RAPID TESTS *S Singh, V Kumari, N Singh Abstract A case of HIV-1 infection, presumably acquired through unsafe blood transfusion in an acute lymphocytic leukemia (ALL) patient, is reported here in whom the two rapid HIV antibody detection kits (HIV-spot and HIV-Scan) failed to diagnose the infection while the sample was strongly positive in microwell ELISA (detect- HIV) on the same day and was confirmed by western blot assay (NEW LAV BLOT-1). However, repeat sample after 15 days was found positive in all the tests. Though the rapid tests are preferred over microwell ELISA because of ease of performance and rapid availability of results, this report confirms low sensitivity of the two rapid tests. This suboptimal sensitivity, particularly in cases of early seroconversion, therefore, must ...

Feline Leukaemia Virus (FeLV) This is one of a series of information handouts written by our vets and nurses for our clients and their pets RINGWOOD HOSPITAL 69 Christchurch Road Ringwood 01425 473683 01425 480849 (Fax) E-mail: Admin@cedarvets. com Website: Cedarvets.com ***** VERWOOD SURGERY 17 Ringwood Road Verwood 01202 825217 ***** FERNDOWN SURGERY 522 Wimborne Road East Ferndown 01202 861622 do not introduce disease to the tom- cat. How do I protect against FeLV? There are several vaccines avail- able against FeLV which can provide 95-100% protection. Two doses of vaccine are given 2-3 weeks apart, and this should begin at about 9 weeks old, when cats are most vulnerable. After that, an annual ...

The Seven Steps Michelle Kenyon Patient Information w w w. k i n g s h e a l t h . c o m Page 2 Page 3 Acknowledgements A u t h o r I would like to take this opportunity to gratefully acknowledge the following people for their help, advice, support and encouragement. Professor GJ Mufti Dr A P a g l i u c a Dr S Devereux Nikki McKeag (EBMT (UK) Nurses and Allied Profession Group) RCN Haematology and Bone Marrow Transplant Nursing Forum I would also like to thank all of the patients who have read and endorsed the book during its development. Their valuable suggestions are incorporated. F i n a l l y, I would like to express my sincere thanks to Leukaemia Research Fund. In particular Sandra Gerscher and Dr David Grant. Michelle Kenyon, BMT Co-ordinator Nurse, King’s College Hospital Published by Leukaemia ...

MEDIA RELEASE MEDIA LINK - The World's Greatest Shave for a Cure website has a dedicated media page, which can be accessed from the home page at www.worldsgreatestshave.com . Here, you can find out more information about WGS and the Leukaemia Foundation, media releases and download WGS images in print-ready format. For immediate release Friday 13 February 2004 LOSING YOUR LOCKS FOR LEUKAEMIA WORLD’S GREATEST SHAVE FOR A CURE – 12 – 13 MARCH 2004 Victorian’s are laying their locks on the line, pledging to shave or colour for the Leukaemia Foundation’s World’s Greatest Shave for a Cure ( WGS) on 12 – 13 March 2004. Sponsored by Triple M, World’s Greatest Shave for a Cure 2004 is expected to involve 10,500 people state-wide, who will take up the “hair-razing” challenge to raise $2.5 million ($10 million nationally) to help in the fight against ...

FELINE LEUKAEMIA VIRUS (FeLV) INFORMATION What is feline leukaemia virus? We might think the human race has had a hard time with all the infectious diseases which can attack us but thank goodness we’re not cats. Not only do they have their equivalent of the Human Immunodeficiency Virus (HIV) in Feline Immunodeficiency Virus (FIV) but they can also be infected by an even nastier immunosuppressive virus-Feline Leukaemia Virus (FeLV). FeLV was first isolated over thirty years ago form a cluster of cats which were suffering from cancers of the white blood cells, hence the name. As time progressed, it became apparent that a more common consequence of infection is a gradual suppression of the immune system. Most cats are dead within two or three years of contracting the infection. The virus belongs to a fascinating group of micro-organisms known as retroviruses. These have the ability ...

British Journal of Haematology, 2001, 113, 439±442 SHORT REPORT Variant Philadelphia translocations in chronic myeloid leukaemia can mimic typical blast crisis chromosome abnormalities or classic t(9;22): a report of two cases Alistair Reid, 1 Susan M. Gribble, 1 Brian J. P. Huntly, 1 Kathryn M. Andrews, 2 Lynda Campbell, 3 Colin D. Grace, 4 Marion E. Wood, 5 Anthony R. Green 1 and Ellie P. Nacheva 1 1 Department of Haematology, University of Cambridge, 2 Department of Haematology, Addenbrookes Hospital, Cambridge, UK, 3 Victorian Cancer Cytogenetics Service, St. Vincents Hospital, Melbourne, Australia, 4 Digital Scientific Ltd, Cambridge, and 5 Department of Haematology, Colchester General ...

1. Abbreviations 1 1. Abbreviations A Adenine Abl Abelson leukaemia ABTS 2,2’-Azino-di-[3-ethylbenzthiazoline sulfonate] Akt Ser/Thr protein kinase known as protein kinase B AP-1 Activator protein 1 Apaf-1 Apoptotic protease activating factor APC Adenomatous Polyposis Coli APS Ammonium peroxydisulfate ATM Ataxia telangiectasia mutated ATP Adenosine triphosphate ATR Ataxia telangiectasia related A.U. Arbitrary units Bax Bcl-2 associated protein X Bcl-2 B-cell lymphoma/ leukaemia bp Base pair BSA Bovine serum albumin C Cytidine CAK Cdk-activating kinase CCNU N-(2-Chloroethyl)-N’-cyclohexyl-N’-nitrosourea cdc Cell-division cycle kinase cdk Cyclin dependent kinase cDNA Complementary DNA strand ch2/ch3 Chromosome ...

Blanche Lane South Mimms Potters Bar Hertfordshire EN6 3QG United Kingdom Assuring the quality of biological medicines Tel: +44 (0)1707 641000 Template version: 16 December 2003 Fax: +44 (0)1707 646730 Page 1 of 4, 93/562 enquiries@nibsc.ac.uk http://www.nibsc.ac.uk National Institute for Biological Standards and Control A World Health Organization International Laboratory For Biological Standards The Institute's UKAS accreditation relates only to our programme of testing for biological medicines. Full details can be found on our Schedule of Accreditation, which is available on request. 1470 LEUKAEMIA INHIBITORY FACTOR (Human rDNA derived) 1st WHO REFERENCE REAGENT NIBSC Code: 93/562 Version 03 1. INTRODUCTION This Standard is the primary biological standard for LIF 2. UNITAGE ...

A Response to the Magnox Sites RSA Consultation Annex 1: Radiation and Health © Mobbs Environmental Investigations, August 2000 page A1-177 Child leukaemia after Chernobyl. Ivanov et. al. Nature, 21/10/93; 365, 702

A Response to the Magnox Sites RSA Consultation Annex 1: Radiation and Health © Mobbs Environmental Investigations, August 2000 page A1-200 The risk of childhood leukaemia near nuclear establishments. J.W. Stather et. al. NRPB-R215, January 1988 Page 2 A Response to the Magnox Sites RSA Consultation Annex 1: Radiation and Health © Mobbs Environmental Investigations, August 2000 page A1-201 Page 3 A Response to the Magnox Sites RSA Consultation Annex 1: Radiation and Health © Mobbs Environmental Investigations, August 2000 page A1-202 Page 4 A Response to the Magnox Sites RSA Consultation Annex 1: Radiation and Health © Mobbs Environmental Investigations, August 2000 page A1-203

A Response to the Magnox Sites RSA Consultation Annex 1: Radiation and Health © Mobbs Environmental Investigations, August 2000 page A1-143 Incidence of leukaemia in young people around La Hague nuclear waste reprocessing plant: a sensitivity analysis. Jean-Francois Viel/ Dominique Pobel. Statistics in Medicine 1995; 14, 2459-2472 Page 2 A Response to the Magnox Sites RSA Consultation Annex 1: Radiation and Health © Mobbs Environmental Investigations, August 2000 page A1-144 Page 3 A Response to the Magnox Sites RSA Consultation Annex 1: Radiation and Health © Mobbs Environmental Investigations, August 2000 page A1-145 Page 4 A Response to the Magnox Sites RSA Consultation Annex 1: Radiation and Health © Mobbs Environmental Investigations, August 2000 page A1-146 Page ...

A Response to the Magnox Sites RSA Consultation Annex 1: Radiation and Health © Mobbs Environmental Investigations, August 2000 page A1-126 Infant leukaemia after in utero exposure to radiation from Chernobyl. E. Petridou et. al. Nature, 25/7/97; 382, 352-353 Page 2 A Response to the Magnox Sites RSA Consultation Annex 1: Radiation and Health © Mobbs Environmental Investigations, August 2000 page A1-127

A Response to the Magnox Sites RSA Consultation Annex 1: Radiation and Health © Mobbs Environmental Investigations, August 2000 page A1-118 Death rates from leukaemia are higher than expected in areas around nuclear sites in Berkshire and Oxfordshire. Chris Busby/Molly Scott Cato. British Medical Journal, 2/8/97; 315, 309

A Response to the Magnox Sites RSA Consultation Annex 1: Radiation and Health © Mobbs Environmental Investigations, August 2000 page A1-119 Childhood leukaemia in US may have risen due to fallout from Chernobyl. Joseph Mangano. British Medical Journal, 19/4/97; 314, 1200

A Response to the Magnox Sites RSA Consultation Annex 1: Radiation and Health © Mobbs Environmental Investigations, August 2000 page A1-120 Case control study of leukaemia among young people near La Hague nuclear reprocessing plant: the environmental hypothesis revisited. Dominique Pobel/Jean-Francois Viel. British Medical Journal, 11/1/97; 314, 101-106 Page 2 A Response to the Magnox Sites RSA Consultation Annex 1: Radiation and Health © Mobbs Environmental Investigations, August 2000 page A1-121 Page 3 A Response to the Magnox Sites RSA Consultation Annex 1: Radiation and Health © Mobbs Environmental Investigations, August 2000 page A1-122 Page 4 A Response to the Magnox Sites RSA Consultation Annex 1: Radiation and Health © Mobbs Environmental Investigations, August 2000 page A1-123 ...

Page 1 of 2 of Instrument No.59 of 2003 Instrument No.59 of 2003 Amendment of Statement of Principles concerning CHRONIC LYMPHOID LEUKAEMIA Veterans’ Entitlements Act 1986 1. As directed by the Specialist Medical Review Council, under subsection 196W(4) of the Veterans’ Entitlements Act 1986 (the Act), the Repatriation Medical Authority amends, pursuant to subsection 196B(10) of the Act, Instrument No.67 of 2001 by: A. in paragraph 5, inserting a new factor (b) as follows: “(b) receiving greater than 25.0 microtesla years of exposure to magnetic fields generated at extremely low frequencies where this dose was accumulated at least 10 years before the clinical onset of chronic lymphoid leukaemia ; or” B. in paragraph 5, renumbering existing factor (b) as (c); C. in paragraph 8, inserting after the definition of “ICD-10-AM ...

NICE Technology Appraisal 50 – Imatinib for chronic myeloid leukaemia Product Clinical condition Indicated for: Not indicated in: Impact of use on NHS Audit data to be collected NICE review date Imatinib Chronic myeloid leukaemia (CML) • People with Philadelphia- chromosome-positive CML in chronic phase in adults who are intolerant of interferon-alpha (IFN- a) therapy, or in whom IFN-a is deemed to have failed to control the disease. • People with Philadelphia- chromosome-positive CML in accelerated phase or blast crisis, provided they have not received imatinib treatment at an earlier stage. • Those who do not meet the previous criteria. • Imatinib costs £12.98 ...

NICE Technology Appraisal 29 Fludarabine in chronic lymphocytic leukaemia Product Condition To be used in: Not to be used in: Impact on the NHS Audit data NICE Review date Fludarabine Chronic B cell lymphocytic leukaemia (CLL) Second line therapy in patients who have failed or are intolerant of first line chemotherapy, where combination therapy would be considered with either cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP); cyclophosphamide, doxorubicin and prednisolone (CAP) or cyclophosphamide, vincristine and prednisolone (CVP) Oral fludarabine should be used in preference to intravenous where possible First line therapy for CLL Increased costs of drug likely to be offset by reduced ...

leukaemia Myelodysplastic syndrome and acute myeloid leukaemia Dr. Edmond S. K. Ma Division of Haematology Department of Pathology The University of Hong Kong Myelodysplastic syndrome A group of clonal haemopoietic stem cell disorder characterized by dysplasia and ineffective haemopoiesis in one or more major myeloid cell line < 20% blasts in blood and bone marrow Myelodysplastic syndrome A disease of the elderly Incidence : 3 – 20 /100,000 Increasing number of therapy related MDS Clinical features: related to cytopenia Etiology: prior chemoradiotherapy, benzene exposure, cigarette smoking, inherited syndromal disorders (e.g. Fanconi’s anaemia) Dyserythropoiesis Nuclear budding Inter-nuclear bridging Karyorrhexis Multinuclearity Megaloblastoid maturation Ringed sideroblast ...

Biochem. J. (2001) 355, 307–314 (Printed in Great Britain) 307 Differential effects of oncostatin M and leukaemia inhibitory factor expression in astrocytoma cells Aneta KASZA*, Krzysztof ROGOWSKI*, Witold KILARSKI*, Radoslaw SOBOTA*, Tytus BERNAS †, Jurek DOBRUCKI†, James TRAVIS ‡, Aleksander KOJ*, Marcin BUGNO* and Tomasz KORDULA* 1 *Department of Animal Biochemistry, Institute of Molecular Biology, Jagiellonian University, 31-120 Krakow, Poland, †Department of Biophysics, Institute of Molecular Biology, Jagiellonian University, 31-120 Krakow, Poland, and ‡Department of Biochemistry and Molecular Biology, University of Georgia, Athens, GA 30602, U.S.A. The effects of the production of two closely related cytokines, oncostatin M (OSM) and leukaemia inhibitory factor (LIF), by astrocytoma cells were investigated using the stable cell line human U373-MG, which expressed ...